APO Research
Talk to an analyst

APO RESEARCH · REPORT

Brucellosis Vaccines

Brucellosis vaccine is a vaccine for cattle, sheep and goats used against brucellosis. Currently, there is no vaccine available for humans.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Brucellosis vaccine is a vaccine for cattle, sheep and goats used against brucellosis. Currently, there is no vaccine available for humans.

Selected research

Market Outlook & Growth Opportunities

Global Brucellosis Vaccines Market Outlook and Growth Opportunities 2026

21 December 2025201 pages

Choose your research edition.

Industry ResearchBrucellosis Vaccines Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal Brucellosis Vaccines Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal Brucellosis Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Brucellosis Vaccines Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Brucellosis Vaccines Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

Brucellosis vaccine is a vaccine for cattle, sheep and goats used against brucellosis. Currently, there is no vaccine available for humans.

Global Brucellosis Vaccines main players are Jinyu, Colorado Serum, Boehringer Ingelheim, Biogenesis-Bago, etc. Global top four manufacturers hold a share above 35%. China is the largest market, with a share about 30%.

This report provides an overview of the global Brucellosis Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Brucellosis Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Brucellosis Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Brucellosis Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

Brucellosis Vaccines Segment by Company

Jinyu

Colorado Serum

Boehringer Ingelheim

Biogenesis-Bago

Vetal Company

CZ Veterinaria

SYVA Laboratorios

Indian Immunologicals

Qilu

Tecnovax

Hester Biosciences

Zoetis

Onderstepoort Biological

Instituto Rosenbusch

Ceva Sante Animale

Calier & Biologicos Laverlam

Biovet

Brucellosis Vaccines Segment by Type

S19 Vaccine

RB51 Vaccine Strain

Brucellosis Vaccines Segment by Application

Cattle

Sheep

Others

Brucellosis Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Brucellosis Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Brucellosis Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Brucellosis Vaccines significant trends, drivers, influence factors in global and regions.

6. To analyze Brucellosis Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Brucellosis Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Brucellosis Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Brucellosis Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Brucellosis Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Brucellosis Vaccines industry.

Chapter 3: Detailed analysis of Brucellosis Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Brucellosis Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Brucellosis Vaccines in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Brucellosis Vaccines Industry Trends Table 2. Brucellosis Vaccines Industry Drivers Table 3. Brucellosis Vaccines Industry Opportunities and Challenges Table 4. Brucellosis Vaccines Industry Restraints Table 5. Global Brucellosis Vaccines Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Brucellosis Vaccines Revenue Share by Company (2021-2026) Table 7. Global Brucellosis Vaccines Sales Volume by Company (M Doses) & (2021-2026) Table 8. Global Brucellosis Vaccines Sales Volume Share by Company (2021-2026) Table 9. Global Brucellosis Vaccines Average Price (USD/K Doses) of Company (2021-2026) Table 10. Global Brucellosis Vaccines Company Ranking, (2024-2026) & (USD Million) Table 11. Global Brucellosis Vaccines Key Company Manufacturing Base & Headquarters Table 12. Global Brucellosis Vaccines Company, Product Type & Application Table 13. Global Brucellosis Vaccines Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Brucellosis Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of S19 Vaccine Table 18. Significant Companies of RB51 Vaccine Strain Table 19. Global Brucellosis Vaccines Sales Volume by Type 2021 VS 2025 VS 2032 (M Doses) Table 20. Global Brucellosis Vaccines Sales Volume by Type (2021-2026) & (M Doses) Table 21. Global Brucellosis Vaccines Sales Volume by Type (2027-2032) & (M Doses) Table 22. Global Brucellosis Vaccines Sales Volume Share by Type (2021-2026) Table 23. Global Brucellosis Vaccines Sales Volume Share by Type (2027-2032) Table 24. Global Brucellosis Vaccines Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Brucellosis Vaccines Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Brucellosis Vaccines Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Brucellosis Vaccines Sales Value Share by Type (2021-2026) Table 28. Global Brucellosis Vaccines Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Cattle Table 30. Significant Companies of Sheep Table 31. Significant Companies of Others Table 32. Global Brucellosis Vaccines Sales Volume by Application 2021 VS 2025 VS 2032 (M Doses) Table 33. Global Brucellosis Vaccines Sales Volume by Application (2021-2026) & (M Doses) Table 34. Global Brucellosis Vaccines Sales Volume by Application (2027-2032) & (M Doses) Table 35. Global Brucellosis Vaccines Sales Volume Share by Application (2021-2026) Table 36. Global Brucellosis Vaccines Sales Volume Share by Application (2027-2032) Table 37. Global Brucellosis Vaccines Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Brucellosis Vaccines Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Brucellosis Vaccines Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Brucellosis Vaccines Sales Value Share by Application (2021-2026) Table 41. Global Brucellosis Vaccines Sales Value Share by Application (2027-2032) Table 42. Global Brucellosis Vaccines Sales by Region: 2021 VS 2025 VS 2032 (M Doses) Table 43. Global Brucellosis Vaccines Sales by Region (2021-2026) & (M Doses) Table 44. Global Brucellosis Vaccines Sales Market Share by Region (2021-2026) Table 45. Global Brucellosis Vaccines Sales by Region (2027-2032) & (M Doses) Table 46. Global Brucellosis Vaccines Sales Market Share by Region (2027-2032) Table 47. Global Brucellosis Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Brucellosis Vaccines Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Brucellosis Vaccines Sales Value Share by Region (2021-2026) Table 50. Global Brucellosis Vaccines Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Brucellosis Vaccines Sales Value Share by Region (2027-2032) Table 52. Global Brucellosis Vaccines Market Average Price (USD/K Doses) by Region (2021-2026) Table 53. Global Brucellosis Vaccines Market Average Price (USD/K Doses) by Region (2027-2032) Table 54. Global Brucellosis Vaccines Sales by Country: 2021 VS 2025 VS 2032 (M Doses) Table 55. Global Brucellosis Vaccines Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Brucellosis Vaccines Sales by Country (2021-2026) & (M Doses) Table 57. Global Brucellosis Vaccines Sales Market Share by Country (2021-2026) Table 58. Global Brucellosis Vaccines Sales by Country (2027-2032) & (M Doses) Table 59. Global Brucellosis Vaccines Sales Market Share by Country (2027-2032) Table 60. Global Brucellosis Vaccines Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Brucellosis Vaccines Sales Value Market Share by Country (2021-2026) Table 62. Global Brucellosis Vaccines Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Brucellosis Vaccines Sales Value Market Share by Country (2027-2032) Table 64. Jinyu Company Information Table 65. Jinyu Business Overview Table 66. Jinyu Brucellosis Vaccines Sales (M Doses), Value (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026) Table 67. Jinyu Brucellosis Vaccines Product Portfolio Table 68. Jinyu Recent Development Table 69. Colorado Serum Company Information Table 70. Colorado Serum Business Overview Table 71. Colorado Serum Brucellosis Vaccines Sales (M Doses), Value (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026) Table 72. Colorado Serum Brucellosis Vaccines Product Portfolio Table 73. Colorado Serum Recent Development Table 74. Boehringer Ingelheim Company Information Table 75. Boehringer Ingelheim Business Overview Table 76. Boehringer Ingelheim Brucellosis Vaccines Sales (M Doses), Value (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026) Table 77. Boehringer Ingelheim Brucellosis Vaccines Product Portfolio Table 78. Boehringer Ingelheim Recent Development Table 79. Biogenesis-Bago Company Information Table 80. Biogenesis-Bago Business Overview Table 81. Biogenesis-Bago Brucellosis Vaccines Sales (M Doses), Value (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026) Table 82. Biogenesis-Bago Brucellosis Vaccines Product Portfolio Table 83. Biogenesis-Bago Recent Development Table 84. Vetal Company Company Information Table 85. Vetal Company Business Overview Table 86. Vetal Company Brucellosis Vaccines Sales (M Doses), Value (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026) Table 87. Vetal Company Brucellosis Vaccines Product Portfolio Table 88. Vetal Company Recent Development Table 89. CZ Veterinaria Company Information Table 90. CZ Veterinaria Business Overview Table 91. CZ Veterinaria Brucellosis Vaccines Sales (M Doses), Value (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026) Table 92. CZ Veterinaria Brucellosis Vaccines Product Portfolio Table 93. CZ Veterinaria Recent Development Table 94. SYVA Laboratorios Company Information Table 95. SYVA Laboratorios Business Overview Table 96. SYVA Laboratorios Brucellosis Vaccines Sales (M Doses), Value (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026) Table 97. SYVA Laboratorios Brucellosis Vaccines Product Portfolio Table 98. SYVA Laboratorios Recent Development Table 99. Indian Immunologicals Company Information Table 100. Indian Immunologicals Business Overview Table 101. Indian Immunologicals Brucellosis Vaccines Sales (M Doses), Value (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026) Table 102. Indian Immunologicals Brucellosis Vaccines Product Portfolio Table 103. Indian Immunologicals Recent Development Table 104. Qilu Company Information Table 105. Qilu Business Overview Table 106. Qilu Brucellosis Vaccines Sales (M Doses), Value (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026) Table 107. Qilu Brucellosis Vaccines Product Portfolio Table 108. Qilu Recent Development Table 109. Tecnovax Company Information Table 110. Tecnovax Business Overview Table 111. Tecnovax Brucellosis Vaccines Sales (M Doses), Value (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026) Table 112. Tecnovax Brucellosis Vaccines Product Portfolio Table 113. Tecnovax Recent Development Table 114. Hester Biosciences Company Information Table 115. Hester Biosciences Business Overview Table 116. Hester Biosciences Brucellosis Vaccines Sales (M Doses), Value (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026) Table 117. Hester Biosciences Brucellosis Vaccines Product Portfolio Table 118. Hester Biosciences Recent Development Table 119. Zoetis Company Information Table 120. Zoetis Business Overview Table 121. Zoetis Brucellosis Vaccines Sales (M Doses), Value (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026) Table 122. Zoetis Brucellosis Vaccines Product Portfolio Table 123. Zoetis Recent Development Table 124. Onderstepoort Biological Company Information Table 125. Onderstepoort Biological Business Overview Table 126. Onderstepoort Biological Brucellosis Vaccines Sales (M Doses), Value (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026) Table 127. Onderstepoort Biological Brucellosis Vaccines Product Portfolio Table 128. Onderstepoort Biological Recent Development Table 129. Instituto Rosenbusch Company Information Table 130. Instituto Rosenbusch Business Overview Table 131. Instituto Rosenbusch Brucellosis Vaccines Sales (M Doses), Value (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026) Table 132. Instituto Rosenbusch Brucellosis Vaccines Product Portfolio Table 133. Instituto Rosenbusch Recent Development Table 134. Ceva Sante Animale Company Information Table 135. Ceva Sante Animale Business Overview Table 136. Ceva Sante Animale Brucellosis Vaccines Sales (M Doses), Value (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026) Table 137. Ceva Sante Animale Brucellosis Vaccines Product Portfolio Table 138. Ceva Sante Animale Recent Development Table 139. Calier & Biologicos Laverlam Company Information Table 140. Calier & Biologicos Laverlam Business Overview Table 141. Calier & Biologicos Laverlam Brucellosis Vaccines Sales (M Doses), Value (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026) Table 142. Calier & Biologicos Laverlam Brucellosis Vaccines Product Portfolio Table 143. Calier & Biologicos Laverlam Recent Development Table 144. Biovet Company Information Table 145. Biovet Business Overview Table 146. Biovet Brucellosis Vaccines Sales (M Doses), Value (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026) Table 147. Biovet Brucellosis Vaccines Product Portfolio Table 148. Biovet Recent Development Table 149. Key Raw Materials Table 150. Raw Materials Key Suppliers Table 151. Brucellosis Vaccines Distributors List Table 152. Brucellosis Vaccines Customers List Table 153. Research Programs/Design for This Report Table 154. Authors List of This Report Table 155. Secondary Sources Table 156. Primary Sources List of Figures Figure 1. Brucellosis Vaccines Product Image Figure 2. Global Brucellosis Vaccines Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Brucellosis Vaccines Sales Value (2021-2032) & (US$ Million) Figure 4. Global Brucellosis Vaccines Sales (2021-2032) & (M Doses) Figure 5. Global Brucellosis Vaccines Sales Average Price (USD/K Doses) & (2021-2032) Figure 6. Global Brucellosis Vaccines Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. S19 Vaccine Image Figure 10. RB51 Vaccine Strain Image Figure 11. Global Brucellosis Vaccines Sales Volume by Type (2021 VS 2025 VS 2032) & (M Doses) Figure 12. Global Brucellosis Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Brucellosis Vaccines Sales Volume Share by Type (2021-2032) Figure 14. Global Brucellosis Vaccines Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Brucellosis Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Brucellosis Vaccines Sales Value Share by Type (2021-2032) Figure 17. Cattle Image Figure 18. Sheep Image Figure 19. Others Image Figure 20. Global Brucellosis Vaccines Sales Volume by Application (2021 VS 2025 VS 2032) & (M Doses) Figure 21. Global Brucellosis Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Brucellosis Vaccines Sales Volume Share by Application (2021-2032) Figure 23. Global Brucellosis Vaccines Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Brucellosis Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Brucellosis Vaccines Sales Value Share by Application (2021-2032) Figure 26. Global Brucellosis Vaccines Sales by Region: 2021 VS 2025 VS 2032 (M Doses) Figure 27. Global Brucellosis Vaccines Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Brucellosis Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Brucellosis Vaccines Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Brucellosis Vaccines Sales Value (2021-2032) & (US$ Million) Figure 31. North America Brucellosis Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Brucellosis Vaccines Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Brucellosis Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Brucellosis Vaccines Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Brucellosis Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Brucellosis Vaccines Sales Value (2021-2032) & (US$ Million) Figure 37. South America Brucellosis Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Brucellosis Vaccines Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Brucellosis Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Brucellosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Brucellosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Brucellosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Brucellosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Brucellosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Brucellosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Brucellosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Brucellosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Brucellosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Brucellosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Brucellosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Brucellosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Brucellosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Brucellosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Brucellosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Brucellosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Brucellosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Brucellosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Brucellosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Brucellosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Brucellosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Brucellosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Brucellosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Brucellosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Brucellosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Brucellosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Brucellosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Brucellosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Brucellosis Vaccines Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Brucellosis Vaccines Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • S19 Vaccine
  • RB51 Vaccine Strain
Applications
  • Cattle
  • Sheep
  • Others
Companies covered
  • Jinyu
  • Colorado Serum
  • Boehringer Ingelheim
  • Biogenesis-Bago
  • Vetal Company
  • CZ Veterinaria
  • SYVA Laboratorios
  • Indian Immunologicals
  • Qilu
  • Tecnovax
  • Hester Biosciences
  • Zoetis
  • Onderstepoort Biological
  • Instituto Rosenbusch
  • Ceva Sante Animale
  • Calier & Biologicos Laverlam
  • Biovet

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Brucellosis Vaccines Sales Value (2021-2032)
  4. 1.2.2 Global Brucellosis Vaccines Sales Volume (2021-2032)
  5. 1.2.3 Global Brucellosis Vaccines Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Brucellosis Vaccines Market Dynamics
  1. 2.1 Brucellosis Vaccines Industry Trends
  2. 2.2 Brucellosis Vaccines Industry Drivers
  3. 2.3 Brucellosis Vaccines Industry Opportunities and Challenges
  4. 2.4 Brucellosis Vaccines Industry Restraints
3 Brucellosis Vaccines Market by Company
  1. 3.1 Global Brucellosis Vaccines Company Revenue Ranking in 2025
  2. 3.2 Global Brucellosis Vaccines Revenue by Company (2021-2026)
  3. 3.3 Global Brucellosis Vaccines Sales Volume by Company (2021-2026)
  4. 3.4 Global Brucellosis Vaccines Average Price by Company (2021-2026)
  5. 3.5 Global Brucellosis Vaccines Company Ranking (2024-2026)
  6. 3.6 Global Brucellosis Vaccines Company Manufacturing Base and Headquarters
  7. 3.7 Global Brucellosis Vaccines Company Product Type and Application
  8. 3.8 Global Brucellosis Vaccines Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Brucellosis Vaccines Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Brucellosis Vaccines Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Brucellosis Vaccines Market by Type
  1. 4.1 Brucellosis Vaccines Type Introduction
  2. 4.1.1 S19 Vaccine
  3. 4.1.2 RB51 Vaccine Strain
  4. 4.2 Global Brucellosis Vaccines Sales Volume by Type
  5. 4.2.1 Global Brucellosis Vaccines Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Brucellosis Vaccines Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Brucellosis Vaccines Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Brucellosis Vaccines Sales Value by Type
  9. 4.3.1 Global Brucellosis Vaccines Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Brucellosis Vaccines Sales Value by Type (2021-2032)
  11. 4.3.3 Global Brucellosis Vaccines Sales Value Share by Type (2021-2032)
5 Brucellosis Vaccines Market by Application
  1. 5.1 Brucellosis Vaccines Application Introduction
  2. 5.1.1 Cattle
  3. 5.1.2 Sheep
  4. 5.1.3 Others
  5. 5.2 Global Brucellosis Vaccines Sales Volume by Application
  6. 5.2.1 Global Brucellosis Vaccines Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Brucellosis Vaccines Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Brucellosis Vaccines Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Brucellosis Vaccines Sales Value by Application
  10. 5.3.1 Global Brucellosis Vaccines Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Brucellosis Vaccines Sales Value by Application (2021-2032)
  12. 5.3.3 Global Brucellosis Vaccines Sales Value Share by Application (2021-2032)
6 Brucellosis Vaccines Regional Sales and Value Analysis
  1. 6.1 Global Brucellosis Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Brucellosis Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global Brucellosis Vaccines Sales by Region: 2021-2026
  4. 6.2.2 Global Brucellosis Vaccines Sales by Region (2027-2032)
  5. 6.3 Global Brucellosis Vaccines Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Brucellosis Vaccines Sales Value by Region (2021-2032)
  7. 6.4.1 Global Brucellosis Vaccines Sales Value by Region: 2021-2026
  8. 6.4.2 Global Brucellosis Vaccines Sales Value by Region (2027-2032)
  9. 6.5 Global Brucellosis Vaccines Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Brucellosis Vaccines Sales Value (2021-2032)
  12. 6.6.2 North America Brucellosis Vaccines Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Brucellosis Vaccines Sales Value (2021-2032)
  15. 6.7.2 Europe Brucellosis Vaccines Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Brucellosis Vaccines Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Brucellosis Vaccines Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Brucellosis Vaccines Sales Value (2021-2032)
  21. 6.9.2 South America Brucellosis Vaccines Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Brucellosis Vaccines Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Brucellosis Vaccines Sales Value Share by Country, 2025 VS 2032
7 Brucellosis Vaccines Country-level Sales and Value Analysis
  1. 7.1 Global Brucellosis Vaccines Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Brucellosis Vaccines Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Brucellosis Vaccines Sales by Country (2021-2032)
  4. 7.3.1 Global Brucellosis Vaccines Sales by Country (2021-2026)
  5. 7.3.2 Global Brucellosis Vaccines Sales by Country (2027-2032)
  6. 7.4 Global Brucellosis Vaccines Sales Value by Country (2021-2032)
  7. 7.4.1 Global Brucellosis Vaccines Sales Value by Country (2021-2026)
  8. 7.4.2 Global Brucellosis Vaccines Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Brucellosis Vaccines Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Brucellosis Vaccines Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Brucellosis Vaccines Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Brucellosis Vaccines Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Brucellosis Vaccines Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Brucellosis Vaccines Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Brucellosis Vaccines Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Brucellosis Vaccines Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Brucellosis Vaccines Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Brucellosis Vaccines Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Brucellosis Vaccines Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Brucellosis Vaccines Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Brucellosis Vaccines Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Brucellosis Vaccines Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Brucellosis Vaccines Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Brucellosis Vaccines Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Brucellosis Vaccines Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Brucellosis Vaccines Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Brucellosis Vaccines Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Brucellosis Vaccines Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Brucellosis Vaccines Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Brucellosis Vaccines Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Brucellosis Vaccines Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Brucellosis Vaccines Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Brucellosis Vaccines Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Brucellosis Vaccines Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Brucellosis Vaccines Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Brucellosis Vaccines Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Brucellosis Vaccines Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Brucellosis Vaccines Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Jinyu
  2. 8.1.1 Jinyu Company Information
  3. 8.1.2 Jinyu Business Overview
  4. 8.1.3 Jinyu Brucellosis Vaccines Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Jinyu Brucellosis Vaccines Product Portfolio
  6. 8.1.5 Jinyu Recent Developments
  7. 8.2 Colorado Serum
  8. 8.2.1 Colorado Serum Company Information
  9. 8.2.2 Colorado Serum Business Overview
  10. 8.2.3 Colorado Serum Brucellosis Vaccines Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Colorado Serum Brucellosis Vaccines Product Portfolio
  12. 8.2.5 Colorado Serum Recent Developments
  13. 8.3 Boehringer Ingelheim
  14. 8.3.1 Boehringer Ingelheim Company Information
  15. 8.3.2 Boehringer Ingelheim Business Overview
  16. 8.3.3 Boehringer Ingelheim Brucellosis Vaccines Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Boehringer Ingelheim Brucellosis Vaccines Product Portfolio
  18. 8.3.5 Boehringer Ingelheim Recent Developments
  19. 8.4 Biogenesis-Bago
  20. 8.4.1 Biogenesis-Bago Company Information
  21. 8.4.2 Biogenesis-Bago Business Overview
  22. 8.4.3 Biogenesis-Bago Brucellosis Vaccines Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Biogenesis-Bago Brucellosis Vaccines Product Portfolio
  24. 8.4.5 Biogenesis-Bago Recent Developments
  25. 8.5 Vetal Company
  26. 8.5.1 Vetal Company Company Information
  27. 8.5.2 Vetal Company Business Overview
  28. 8.5.3 Vetal Company Brucellosis Vaccines Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Vetal Company Brucellosis Vaccines Product Portfolio
  30. 8.5.5 Vetal Company Recent Developments
  31. 8.6 CZ Veterinaria
  32. 8.6.1 CZ Veterinaria Company Information
  33. 8.6.2 CZ Veterinaria Business Overview
  34. 8.6.3 CZ Veterinaria Brucellosis Vaccines Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 CZ Veterinaria Brucellosis Vaccines Product Portfolio
  36. 8.6.5 CZ Veterinaria Recent Developments
  37. 8.7 SYVA Laboratorios
  38. 8.7.1 SYVA Laboratorios Company Information
  39. 8.7.2 SYVA Laboratorios Business Overview
  40. 8.7.3 SYVA Laboratorios Brucellosis Vaccines Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 SYVA Laboratorios Brucellosis Vaccines Product Portfolio
  42. 8.7.5 SYVA Laboratorios Recent Developments
  43. 8.8 Indian Immunologicals
  44. 8.8.1 Indian Immunologicals Company Information
  45. 8.8.2 Indian Immunologicals Business Overview
  46. 8.8.3 Indian Immunologicals Brucellosis Vaccines Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Indian Immunologicals Brucellosis Vaccines Product Portfolio
  48. 8.8.5 Indian Immunologicals Recent Developments
  49. 8.9 Qilu
  50. 8.9.1 Qilu Company Information
  51. 8.9.2 Qilu Business Overview
  52. 8.9.3 Qilu Brucellosis Vaccines Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Qilu Brucellosis Vaccines Product Portfolio
  54. 8.9.5 Qilu Recent Developments
  55. 8.10 Tecnovax
  56. 8.10.1 Tecnovax Company Information
  57. 8.10.2 Tecnovax Business Overview
  58. 8.10.3 Tecnovax Brucellosis Vaccines Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Tecnovax Brucellosis Vaccines Product Portfolio
  60. 8.10.5 Tecnovax Recent Developments
  61. 8.11 Hester Biosciences
  62. 8.11.1 Hester Biosciences Company Information
  63. 8.11.2 Hester Biosciences Business Overview
  64. 8.11.3 Hester Biosciences Brucellosis Vaccines Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Hester Biosciences Brucellosis Vaccines Product Portfolio
  66. 8.11.5 Hester Biosciences Recent Developments
  67. 8.12 Zoetis
  68. 8.12.1 Zoetis Company Information
  69. 8.12.2 Zoetis Business Overview
  70. 8.12.3 Zoetis Brucellosis Vaccines Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Zoetis Brucellosis Vaccines Product Portfolio
  72. 8.12.5 Zoetis Recent Developments
  73. 8.13 Onderstepoort Biological
  74. 8.13.1 Onderstepoort Biological Company Information
  75. 8.13.2 Onderstepoort Biological Business Overview
  76. 8.13.3 Onderstepoort Biological Brucellosis Vaccines Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Onderstepoort Biological Brucellosis Vaccines Product Portfolio
  78. 8.13.5 Onderstepoort Biological Recent Developments
  79. 8.14 Instituto Rosenbusch
  80. 8.14.1 Instituto Rosenbusch Company Information
  81. 8.14.2 Instituto Rosenbusch Business Overview
  82. 8.14.3 Instituto Rosenbusch Brucellosis Vaccines Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Instituto Rosenbusch Brucellosis Vaccines Product Portfolio
  84. 8.14.5 Instituto Rosenbusch Recent Developments
  85. 8.15 Ceva Sante Animale
  86. 8.15.1 Ceva Sante Animale Company Information
  87. 8.15.2 Ceva Sante Animale Business Overview
  88. 8.15.3 Ceva Sante Animale Brucellosis Vaccines Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Ceva Sante Animale Brucellosis Vaccines Product Portfolio
  90. 8.15.5 Ceva Sante Animale Recent Developments
  91. 8.16 Calier & Biologicos Laverlam
  92. 8.16.1 Calier & Biologicos Laverlam Company Information
  93. 8.16.2 Calier & Biologicos Laverlam Business Overview
  94. 8.16.3 Calier & Biologicos Laverlam Brucellosis Vaccines Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Calier & Biologicos Laverlam Brucellosis Vaccines Product Portfolio
  96. 8.16.5 Calier & Biologicos Laverlam Recent Developments
  97. 8.17 Biovet
  98. 8.17.1 Biovet Company Information
  99. 8.17.2 Biovet Business Overview
  100. 8.17.3 Biovet Brucellosis Vaccines Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Biovet Brucellosis Vaccines Product Portfolio
  102. 8.17.5 Biovet Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Brucellosis Vaccines Value Chain Analysis
  2. 9.1.1 Brucellosis Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Brucellosis Vaccines Sales Mode & Process
  6. 9.2 Brucellosis Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Brucellosis Vaccines Distributors
  9. 9.2.3 Brucellosis Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst